A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting

E. Antonio Chiocca, Khalid M. Abbed, Stephen Tatter, David N. Louis, Fred H. Hochberg, Fred Barker, Jean Kracher, Stuart A. Grossman, Joy D. Fisher, Kathryn Carson, Mark Rosenblum, Tom Mikkelsen, Jeff Olson, James Markert, Steven Rosenfeld, L. Burt Nabors, Steven Brem, Surasak Phuphanich, Scott Freeman, Rick KaplanJames Zwiebel

Research output: Contribution to journalArticle

262 Citations (Scopus)

Abstract

ONYX-015 is an oncolytic virus untested as a treatment for malignant glioma. The NABTT CNS Consortium conducted a dose-escalation trial of intracerebral injections of ONYX-015. Cohorts of six patients at each dose level received doses of vector from 107 plaque-forming units (pfu) to 1010 pfu into a total of 10 sites within the resected glioma cavity. Adverse events were identified on physical exams and testing of hematologic, renal, and liver functions. Efficacy data were obtained from serial MRI scans. None of the 24 patients experienced serious adverse events related to ONYX-015. The maximum tolerated dose was not reached at 1010 pfu. The median time to progression after treatment with ONYX-015 was 46 days (range 13 to 452 + days). The median survival time was 6.2 months (range 1.3 to 28.0 + months). One patient has not progressed and 1 patient showed regression of interval-increased enhancement. With more than 19 months of follow-up, 1/6 recipients at a dose of 109 and 2/6 at a dose of 1010 pfu remain alive. In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 1010 pfu.

Original languageEnglish (US)
Pages (from-to)958-966
Number of pages9
JournalMolecular Therapy
Volume10
Issue number5
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

Adenoviridae
Glioma
Injections
Oncolytic Viruses
Maximum Tolerated Dose
ONYX015
Magnetic Resonance Imaging
Kidney
Survival
Liver
Therapeutics

Keywords

  • Adenovirus
  • Brain tumor
  • Clinical trial
  • Conditionally replicating adenoviruses
  • Experimental therapy
  • Gene therapy
  • Glioma
  • Oncolytic virus
  • ONYX-015
  • Virotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. / Chiocca, E. Antonio; Abbed, Khalid M.; Tatter, Stephen; Louis, David N.; Hochberg, Fred H.; Barker, Fred; Kracher, Jean; Grossman, Stuart A.; Fisher, Joy D.; Carson, Kathryn; Rosenblum, Mark; Mikkelsen, Tom; Olson, Jeff; Markert, James; Rosenfeld, Steven; Nabors, L. Burt; Brem, Steven; Phuphanich, Surasak; Freeman, Scott; Kaplan, Rick; Zwiebel, James.

In: Molecular Therapy, Vol. 10, No. 5, 01.11.2004, p. 958-966.

Research output: Contribution to journalArticle

Chiocca, EA, Abbed, KM, Tatter, S, Louis, DN, Hochberg, FH, Barker, F, Kracher, J, Grossman, SA, Fisher, JD, Carson, K, Rosenblum, M, Mikkelsen, T, Olson, J, Markert, J, Rosenfeld, S, Nabors, LB, Brem, S, Phuphanich, S, Freeman, S, Kaplan, R & Zwiebel, J 2004, 'A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting', Molecular Therapy, vol. 10, no. 5, pp. 958-966. https://doi.org/10.1016/j.ymthe.2004.07.021
Chiocca, E. Antonio ; Abbed, Khalid M. ; Tatter, Stephen ; Louis, David N. ; Hochberg, Fred H. ; Barker, Fred ; Kracher, Jean ; Grossman, Stuart A. ; Fisher, Joy D. ; Carson, Kathryn ; Rosenblum, Mark ; Mikkelsen, Tom ; Olson, Jeff ; Markert, James ; Rosenfeld, Steven ; Nabors, L. Burt ; Brem, Steven ; Phuphanich, Surasak ; Freeman, Scott ; Kaplan, Rick ; Zwiebel, James. / A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. In: Molecular Therapy. 2004 ; Vol. 10, No. 5. pp. 958-966.
@article{0e2fcdc38f1b452595252f6fd291967b,
title = "A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting",
abstract = "ONYX-015 is an oncolytic virus untested as a treatment for malignant glioma. The NABTT CNS Consortium conducted a dose-escalation trial of intracerebral injections of ONYX-015. Cohorts of six patients at each dose level received doses of vector from 107 plaque-forming units (pfu) to 1010 pfu into a total of 10 sites within the resected glioma cavity. Adverse events were identified on physical exams and testing of hematologic, renal, and liver functions. Efficacy data were obtained from serial MRI scans. None of the 24 patients experienced serious adverse events related to ONYX-015. The maximum tolerated dose was not reached at 1010 pfu. The median time to progression after treatment with ONYX-015 was 46 days (range 13 to 452 + days). The median survival time was 6.2 months (range 1.3 to 28.0 + months). One patient has not progressed and 1 patient showed regression of interval-increased enhancement. With more than 19 months of follow-up, 1/6 recipients at a dose of 109 and 2/6 at a dose of 1010 pfu remain alive. In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 1010 pfu.",
keywords = "Adenovirus, Brain tumor, Clinical trial, Conditionally replicating adenoviruses, Experimental therapy, Gene therapy, Glioma, Oncolytic virus, ONYX-015, Virotherapy",
author = "Chiocca, {E. Antonio} and Abbed, {Khalid M.} and Stephen Tatter and Louis, {David N.} and Hochberg, {Fred H.} and Fred Barker and Jean Kracher and Grossman, {Stuart A.} and Fisher, {Joy D.} and Kathryn Carson and Mark Rosenblum and Tom Mikkelsen and Jeff Olson and James Markert and Steven Rosenfeld and Nabors, {L. Burt} and Steven Brem and Surasak Phuphanich and Scott Freeman and Rick Kaplan and James Zwiebel",
year = "2004",
month = "11",
day = "1",
doi = "10.1016/j.ymthe.2004.07.021",
language = "English (US)",
volume = "10",
pages = "958--966",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting

AU - Chiocca, E. Antonio

AU - Abbed, Khalid M.

AU - Tatter, Stephen

AU - Louis, David N.

AU - Hochberg, Fred H.

AU - Barker, Fred

AU - Kracher, Jean

AU - Grossman, Stuart A.

AU - Fisher, Joy D.

AU - Carson, Kathryn

AU - Rosenblum, Mark

AU - Mikkelsen, Tom

AU - Olson, Jeff

AU - Markert, James

AU - Rosenfeld, Steven

AU - Nabors, L. Burt

AU - Brem, Steven

AU - Phuphanich, Surasak

AU - Freeman, Scott

AU - Kaplan, Rick

AU - Zwiebel, James

PY - 2004/11/1

Y1 - 2004/11/1

N2 - ONYX-015 is an oncolytic virus untested as a treatment for malignant glioma. The NABTT CNS Consortium conducted a dose-escalation trial of intracerebral injections of ONYX-015. Cohorts of six patients at each dose level received doses of vector from 107 plaque-forming units (pfu) to 1010 pfu into a total of 10 sites within the resected glioma cavity. Adverse events were identified on physical exams and testing of hematologic, renal, and liver functions. Efficacy data were obtained from serial MRI scans. None of the 24 patients experienced serious adverse events related to ONYX-015. The maximum tolerated dose was not reached at 1010 pfu. The median time to progression after treatment with ONYX-015 was 46 days (range 13 to 452 + days). The median survival time was 6.2 months (range 1.3 to 28.0 + months). One patient has not progressed and 1 patient showed regression of interval-increased enhancement. With more than 19 months of follow-up, 1/6 recipients at a dose of 109 and 2/6 at a dose of 1010 pfu remain alive. In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 1010 pfu.

AB - ONYX-015 is an oncolytic virus untested as a treatment for malignant glioma. The NABTT CNS Consortium conducted a dose-escalation trial of intracerebral injections of ONYX-015. Cohorts of six patients at each dose level received doses of vector from 107 plaque-forming units (pfu) to 1010 pfu into a total of 10 sites within the resected glioma cavity. Adverse events were identified on physical exams and testing of hematologic, renal, and liver functions. Efficacy data were obtained from serial MRI scans. None of the 24 patients experienced serious adverse events related to ONYX-015. The maximum tolerated dose was not reached at 1010 pfu. The median time to progression after treatment with ONYX-015 was 46 days (range 13 to 452 + days). The median survival time was 6.2 months (range 1.3 to 28.0 + months). One patient has not progressed and 1 patient showed regression of interval-increased enhancement. With more than 19 months of follow-up, 1/6 recipients at a dose of 109 and 2/6 at a dose of 1010 pfu remain alive. In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 1010 pfu.

KW - Adenovirus

KW - Brain tumor

KW - Clinical trial

KW - Conditionally replicating adenoviruses

KW - Experimental therapy

KW - Gene therapy

KW - Glioma

KW - Oncolytic virus

KW - ONYX-015

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=7044228126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044228126&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.07.021

DO - 10.1016/j.ymthe.2004.07.021

M3 - Article

C2 - 15509513

AN - SCOPUS:7044228126

VL - 10

SP - 958

EP - 966

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -